NOIDS.wiki
Calculator
Shop Potency Calculator
Cannabis Science

7-Hydroxy-cannabidiol (7-OH-CBD): Specs, Where It Fits & Evidence

Cannabinoid · Metabolite

NoMetaboliteCBD metabolitePreclinical

7-Hydroxy-cannabidiol (7-OH-CBD) is a cannabinoid metabolite formed in the body, in the CBD metabolite group. The major active metabolite the liver makes from CBD.

Full name
7-Hydroxy-cannabidiol
Abbreviation
7-OH-CBD
Molecular formula
C21H30O3
Class / family
CBD metabolite
Precursor / from
CBD (liver CYP)
Intoxicating?
No
Research status
Preclinical

Where it fits

7-Hydroxy-cannabidiol (7-OH-CBD) derives from CBD (liver CYP). See the Synthetic & altered cannabinoids index for how it relates to the rest of the family.

What the research shows

7-Hydroxy-cannabidiol (7-OH-CBD) has preclinical-level evidence; see the class index and related compounds for cited studies.

Frequently Asked Questions

Is 7-hydroxy-CBD (7-OH-CBD) intoxicating?

No. 7-Hydroxy-cannabidiol (7-OH-CBD) is non-intoxicating and does not activate CB1 receptors in the way delta-9-THC or 11-hydroxy-THC does.

Which liver enzymes convert CBD into 7-OH-CBD?

Human pharmacokinetic and in-vitro microsomal studies show that cytochrome P450 2C19 (CYP2C19) is the primary enzyme responsible for 7-hydroxylation of CBD into 7-OH-CBD, with minor contribution from CYP2C9.

Is 7-OH-CBD pharmacologically active?

Yes. Unlike the downstream metabolite 7-COOH-CBD, 7-OH-CBD retains anticonvulsant activity in preclinical seizure models and contributes to the clinical pharmacology of oral cannabidiol.

Sources

  1. Beers, J. L., Fu, D., & Jackson, K. D. (2021). Cytochrome P450-catalyzed metabolism of cannabidiol to the active metabolite 7-hydroxy-cannabidiol. Drug Metabolism and Disposition, 49(10), 882-891. PubMed 34045238
  2. Jiang, R., Yamaori, S., Takeda, S.,山本, I., & Watanabe, K. (2011). Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sciences, 89(5-6), 165-170. PubMed 21704641
  3. Ujváry, I., & Hanuš, L. (2016). Human metabolites of cannabidiol: a review on their formation, biological activity, and relevance in therapy. Cannabis and Cannabinoid Research, 1(1), 90-101. PubMed 28861484
  4. Taylor, L., Gidal, B., Blakey, G., Tayo, B., & Morrison, G. (2018). A Phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs, 32(11), 1053-1067. PubMed 30374606

Part of the NOIDS cannabinoids index. Educational reference, not medical advice.

This article is for educational purposes only. Always follow local laws regarding cannabis preparation and use.

Scroll to Top